Press Releases

01.10.2026

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

01.05.2026

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.18.2025

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

12.17.2025

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

12.16.2025

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

12.12.2025

Pfizer Declares First-Quarter 2026 Dividend

12.10.2025

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

12.09.2025

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

12.06.2025

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

12.01.2025

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

11.21.2025

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

11.13.2025

Pfizer Completes Acquisition of Metsera